Objective-To investigate the contribution of polymorphisms in multiple candidate genes to cardiovascular disease (CVD) risk in a large cohort of patients with heterozygous familial hypercholesterolemia (FH). Methods and Results-We genotyped 1940 FH patients for 65 polymorphisms in 36 candidate genes. During 91.451 person-years, 643 (33.1%) patients had at least 1 cardiovascular event. Multifactorial Cox survival analysis revealed that the G20210A polymorphism in the prothrombin gene was strongly associated with a significantly increased CVD risk (GA versus GG; PϽ0.001). Conclusions-In a large cohort of FH patients, we found that the G20210A polymorphism in the prothrombin gene is strongly associated with CVD risk. Our results constitute a step forward in the unraveling of the hereditary propensity toward CVD in FH and might lead to better risk stratification and hence to more tailored therapy for CVD prevention.
F amilial hypercholesterolemia (FH) is a common hereditary disease, characterized by elevated levels of plasma low-density lipoprotein cholesterol (LDL-C) and premature cardiovascular disease (CVD). 1 Characteristically, the mean age of onset of CVD is between 40 and 45 years in male FH patients and in female FH patients 10 years later. 1, 2 Nevertheless, the phenotypic expression of this disorder, in terms of onset and severity of atherosclerotic vascular disease, varies considerably. 3 Unfortunately, a paucity of solid data exists on factors that contribute to these phenotypic differences. Previous studies have mostly focused on classical CVD risk factors and the functional variety among LDL receptor mutations. 4 -6 Although both influence the occurrence of CVD, they can only partially explain the observed large differences. We recently studied the contribution of classical risk factors to CVD in a large cohort of FH patients and demonstrated that Ͻ20% of the variation in CVD occurrence could be explained by these risk factors alone. 7 Therefore, other still unknown and possibly genetic factors play an undeniable role in the development of CVD in these patients. Genetic differences affect susceptibility to disease and whereas premature atherosclerosis can be linked in rare cases to single-gene disorders, most individuals do not carry such DNA defects. The "common disorder, common variant" theory predicts that the majority of population-attributable variation in susceptibility to prev-alent disease is caused by variants that occur in high frequency in multiple genes. 8 Such genetic variation may also play an important role in the development of CVD in FH. This is substantiated by the fact that clustering of CVD occurs in FH kindred. 9 Unfortunately, large-scale association studies involving multiple polymorphisms are lacking in FH. Our objective, therefore, was to investigate the contribution of polymorphisms in multiple candidate genes to CVD risk in a large cohort of patients with heterozygous FH.
Methods

Study Design and Study Population
The present investigation was a retrospective, multicenter, cohort study. The study design and study population have been described elsewhere. 7 Briefly, lipid clinics in the Netherlands submit DNA samples from clinically suspected FH patients to a central laboratory for LDL receptor mutation analysis. 10 We randomly selected hypercholesterolemic patients from this DNA bank database with the aid of a computer program (Microsoft Excel). These patients had been referred from 27 lipid clinics throughout the Netherlands (Figure I, available online at http://atvb.ahajournals.org).
Phenotypic data (including detailed information on CVD) were acquired by reviewing patient's medical records by a trained team of data collectors. 7 Guidelines for data collection from medical records were constructed for the purpose of the study and have been published. 11 Written informed consent was obtained from all living patients. The Ethics Institutional Review Board of each participating hospital approved the protocol.
Power Calculation
To calculate CVD risk associated with genetic polymorphisms, at least 2000 FH patients were needed to reach a power of 80% to detect an odds ratio of 1.9 or more for carriers of the rare allele (please see http://atvb.ahajournals.org for the exact power calculation).
Selection of Patients and Inclusion Criteria
On reviewing 4000 medical records, a total of 2400 patients fulfilled the inclusion and exclusion criteria for participation and were included in the study (Figure I and Table I , available online at http://atvb.ahajournals.org). The FH diagnostic criteria were based on internationally established criteria. [12] [13] [14] 
Selection of DNA Polymorphisms and Genetic Analyses
We genotyped 65 polymorphisms in 36 candidate genes that were previously implicated in CVD. 15 Complete genotypes for all 65 polymorphisms could be obtained for 1940 (80.1%) of patients. In the remaining 460 patients, complete genotyping was impaired by technical difficulties. First, the amount of DNA was insufficient for adequate amplification in 235 patients. Among the remaining samples, complete genotyping for all polymorphisms was not possible. The missing data rate ranged from 0.51% to 5.3%, with an average rate of 1.7%. These patients did not differ clinically from the 1940 patients and were excluded from further analyses. Genomic DNA was extracted from peripheral blood leukocytes by standard procedures. Each sample was amplified using 2 pools of biotinylated polymerase chain reaction primers. Each polymerase chain reaction product pool was then hybridized to a linear array of sequencespecific oligonucleotide probes and alleles were detected using a hydrogen peroxidase-based chromogenic reaction, essentially as described previously. 15 Samples were blinded for genotyping. The accuracy of genotyping in 500 randomly selected DNA samples was assessed by re-analysis of several polymorphisms in 3 genes (CETP, MTHFR, LPL). Less than 0.5% of discordant results were found.
Statistical Analysis
Differences between subgroups were tested with 2 statistics or independent sample t test (for triglycerides [skewed distribution] on log-transformed data). To adjust for the effects of age and sex, we used multiple linear or logistic regression. Allele frequencies were calculated by genotype counting and for each (biallelic) polymorphism the deviation from Hardy-Weinberg equilibrium was tested by a 2 test with 1 degree of freedom. A likelihood ratio test was used to detect pair-wise linkage disequilibrium 16 and the extent of disequilibrium was expressed in terms of DЈϭD/D max or D/D min . 17 Cox proportional hazard regression with backward stepwise selection was used to model the association of multiple polymorphisms simultaneously with the occurrence of CVD. Polymorphisms were treated as categorical variables and patients homozygous for the common allele were used as the reference category. Follow-up started at birth and ended for each individual at the date of the first occurrence of established CVD. Patients without CVD were censored at the date of the last lipid clinic visit or at the date of death attributable to other causes. Because polymorphisms might express their untoward effects by way of, for example, hypertension, diabetes mellitus, obesity, or dyslipidemia, we did not introduce these factors as covariates in our models. Instead, we added those covariates that function independently from the polymorphisms: sex and smoking (time-dependent). For smoking, we implemented a linearly decreasing risk effect for the 3 years after cessation. 18 Statistical analyses were performed using SPSS software (version 11.5; Chicago, Ill). Polymorphisms with PϽ0.05 for the likelihood ratio test were considered to be suggestively associated; those with PϽ0.001 were considered statistically significant.
Results
Clinical characteristics of the 1940 completely genotyped patients are described in Table 1 . During 91.451 personyears, 643 (33.1%) patients had at least 1 cardiovascular event, including 29 individuals who died from documented CVD events. Mean age of onset of CVD was 48.2 years. Patients with CVD were older, more often males and smokers, and had a higher prevalence of hypertension and diabetes mellitus. More obesity and higher total cholesterol levels were also observed among CVD patients but were not significant after adjustment for age and sex. LDL-C levels did not differ between CVD and non-CVD patients. High-density lipoprotein cholesterol levels were lower (1.15Ϯ0.32 versus 1.24Ϯ0.36 mmol/L; PϽ0.001) and median triglyceride levels Values are given as mean levelsϮSD, except when given as percentages. Triglycerides are given as median with the interquartile range between brackets.
CVDϩ indicates cardiovascular disease present; CVDϪ, cardiovascular disease absent; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, not applicable.
higher (1.76 versus 1.48 mmol/L; PϽ0.001) in patients with CVD.
The 36 genes and 65 polymorphisms examined in the study and the frequencies of the least common alleles of the polymorphisms are presented in Table 2 . All but 11 of the 65 polymorphisms studied were in Hardy-Weinberg equilibrium. The same polymorphisms showed deviation from Hardy-Weinberg equilibrium in patients with and without cardiovascular disease (data not shown). For 3 polymorphisms in the CETP gene (Asp442Gly, ϩ1 GϾA, and ϩ3insT/in14), only homozygous wild-type individuals were found, which were excluded from further analyses.
Multifactorial Cox survival analysis, which included the 62 polymorphisms simultaneously, adjusted for sex and smoking, revealed that the G20210A polymorphism in the prothrombin gene exhibited the strongest association with an increased risk of CVD (GA versus GG; PϽ0.001) ( Table 3) . Heterozygous carriers of the G20210A polymorphism showed clearly reduced cardiovascular event-free survival rates (Figure) . Subgroup analyses for gender, total cholesterol, LDL-C, high-density lipoprotein cholesterol, and triglyceride tertiles and year of birth (before 1930, 1930 to 1949, 1950 to 1969, or after 1970) were performed. For each subgroup, hazard ratios (HR) of Ϸ2.0 (not significant) were found, suggesting that the observed HR is not caused by a specific subgroup within the present population (data not shown). In addition, 4 other polymorphisms were identified to be suggestively associated with the risk of CVD (PϽ0.05). We investigated and confirmed the associations between specific polymorphisms and hypertension, diabetes mellitus, obesity, and dyslipidemia, which were not introduced as covariates in our models. However, to enable comparison of our results with those from earlier studies, we performed the same Cox regression model while adjusting not only for sex and smoking but also for hypertension (time-dependent), diabetes mellitus (time-dependent), body mass index, total cholesterol, LDL-C, high-density lipoprotein cholesterol, triglycerides, lipoprotein(a), and homocysteine levels. The detected HRs were similar (data not shown). The genotype distributions of polymorphisms associated with cardiovascular disease are depicted in Table 5 .
Discussion
We investigated the contribution of a large number of polymorphisms in multiple candidate genes to CVD risk in FH patients. Strikingly, the G20210A polymorphism in the prothrombin gene was most strongly related to a significantly increased CVD risk. In addition, 4 other polymorphisms were suggestively associated with CVD (PϽ0.05). Two were associated with increased CVD risk, namely the Met235Thr variant in the angiotensinogen gene and the Thr347Ser variant in the apoA4 gene. In contrast, the Ser311Cys substitution in the paraoxonase-2 gene and the C1100T variant in the apoC3 gene were associated with decreased CVD risk. To our knowledge, this is the largest exploratory study on the association of genetic variants and CVD risk in FH.
The strengths of the present study lie in several areas. To begin with, by recruiting patients from all over the country, and by using our patient registration database, we minimized selection bias toward large families and genetically isolated communities. Moreover, by choosing a cohort design and deriving our "cases" and "controls" from a common population, we reduced the chance of population stratification and spurious associations.
Second, the large size of the cohort provided sufficient statistical power to detect relatively small relative risks or HRs. Our initial power statement was based on calculating an odds ratio. A power statement for HR was difficult to formulate, because other, less easy to predict, assumptions like median survival in control patients would have had to have been included in that power analysis. In retrospect, the average median survival of homozygous wild-type patients was 60 years, with a maximum follow-up of 85 years. Thus, in our cohort, HR of 1.6 (or 0.7 protective) could have been detected with a power of 80% (with a Bonferroni corrected 2-sided Pϭ0.0008) using 1940 patients and assuming that 10% of the patients carried at least 1 rare allele. Because the carrier frequency was even higher than 10% for most polymorphisms, the actual power to detect a HR of 1.6 or higher exceeded 80%.
Last, we applied more stringent criteria for statistical significance to avoid problems of "repetitive testing," which often occurs in studies of multiple polymorphisms. Furthermore, to examine possible false-positive associations caused by linkage disequilibrium between loci, we simultaneously assessed the effects of multiple polymorphisms in a multifactorial Cox model. Importantly, a cohort study design enabled us to determine HRs. Many association studies have had case-control designs with odds ratios as the outcome parameter. Whereas odds ratios mimic relative risks remarkably well when the outcome of interest is rare, this is not the case for CVD in FH, in which odds ratios might exaggerate the actual risk.
Several limitations of our study should also be mentioned. First, in this retrospective study, the primary source of data was the patient's medical records. Medical records are primarily intended for patient care and not for research purposes. Second, no standardized information was available on lifestyle factors, such as dietary habits and physical activity. As a result, the interaction between these environmental factors and genetic variants could not be studied.
Third, our study included patients that were referred to a lipid clinic. In theory, patients with the most detrimental genetic profiles might have died before referral. Therefore, genetic polymorphisms associated with more severe CVD or early death could have been missed, leading to an underestimation of the risk. Fourth, 11 of the 65 polymorphisms studied were not in Hardy-Weinberg equilibrium. The exact reason for the deviation is not known and we can only speculate on this. Importantly, the deviation from Hardy-Weinberg equilibrium is not because of mixed ethnic groups, because the Dutch population is known to be a homogenous one. More than 99% of our patients were white and patients were randomly selected from all over the country. In addition, most deviations were caused by an excess of heterozygotes, which makes genotyping errors unlikely. Furthermore, the accuracy of genotyping in 500 randomly selected DNA samples was assessed by re-analysis of several polymorphisms in three genes, revealing that Ͻ0.5% of the results were discordant. However, it must be stressed that these 3 re-analyzed polymorphisms were not among the polymorphisms that were not in Hardy-Weinberg equilibrium. Finally, and most importantly, the 11 SNPs showed the same deviation from Hardy-Weinberg equilibrium in patients with CVD as well as in patients without CVD; therefore, we are of the opinion that this has not affected our results significantly. Fifth, it should be stressed that by the nature of this exploratory study the impact of the polymorphisms on intermediate end points such as coagulation factors (eg, prothrombin), blood pressure levels, angiotensinogen levels, and apolipoprotein levels, could not be assessed in the present study. Therefore, we could not determine the relationship of these intermediate end points with CVD, nor the subsequent pathological mechanisms involved in the development of CVD.
Our results are in line with earlier findings. The prothrombin mutation G20210A leads to increased plasma levels of prothrombin and an increased risk of venous thrombosis. 19 Many studies have focused on the causative role of this mutation in arterial disease, often with negative results. 20, 21 However, in a comprehensive meta-analysis investigating the possible link between the G20210A prothrombin gene variant and different forms of premature ischemic heart disease in 12 043 patients, the G20210A polymorphism was shown to be a significant risk factor for myocardial infarction at a young age. 22 In patients aged 55 years and younger, the odds ratio was 1.77 (95% CI, 1.16 to 3.42); in those aged 45 years and younger, the odds ratio was 2.30 (95% CI, 1.27 to 4.59). These odds ratios are similar to the HRs found in our study. In another meta-analysis, the association between the G20210A variant and arterial circulatory events was confirmed. 23 In addition, 2 other large studies showed a pronounced effect of this polymorphism on CVD events in dyslipidemic patients. 24, 25 Although the relationship between this prothrombin mutation and CVD remains the subject of debate in non-FH populations, these findings support the strong association between G20210A carriership and premature CVD risk in our FH patients who have severe dyslipidemia from birth onwards.
Recently, the M235T polymorphism in the angiotensinogen gene was associated with increased levels of angiotensinogen and a corresponding increase in the risk of hypertension, as assessed in 45 267 individuals. 26 However, a relationship between this variant and CVD risk has never been established in a large-scale study. Again, in our FH patients, the combined effect of elevated angiotensinogen and LDL-C levels might explain the increased risk of CVD.
We identified 2 common variants in the ApoA1-C3-A4-A5 gene cluster to be suggestively associated with CVD risk (Thr347Ser in apoA4 and C1100T in apoC3). Both appear to have (statistically) independent effects, because they remained significant in the multifactorial model and the estimated HRs of the univariate and multifactorial model were almost identical for both variants (data not shown). Apolipoproteins play a central role in lipid metabolism and this cluster of apolipoprotein genes has been identified as a locus with significant effects on triglyceride levels. [27] [28] [29] Remarkably, in the first prospective study on genetic variants in this gene cluster and CVD risk in the general population, exactly the same 2 polymorphisms were associated with an increase and decrease in risk, respectively. 30 However, in their multifactorial model, which also included other known risk factors such as body mass index and blood pressure, only the Thr347Ser variant remained significantly associated with CVD risk. They concluded that the apparent protective effect of C1100T in the apoC3 gene is most likely caused by strong linkage disequilibrium across the gene cluster. When body mass index, blood pressure, total cholesterol, and triglycerides were also added to our multifactorial model, the effect of the Thr347Ser variant was no longer significant (data not shown). However, this apparent discrepancy could be caused by differences in genotype frequencies between the 2 popu-lations. Furthermore, in both populations the inference of functionality for these variants was hampered by the almost complete absence of patients homozygous for both the 347Ser and the 1100T allele.
Many studies support the antiatherogenic role of paraoxonase-1, an HDL-associated enzyme. 31 The protective effect is generally considered to be caused by the ability of paraoxonase-1 to attenuate oxidative modification of lipoprotein particles. Paraoxonase-2, a family member of paraoxonase-1, is reported to have antioxidant properties and antiatherogenic capacities as well, although its exact physiological role is still unknown. 31 Our results confirm a relationship between paraoxonase-2 and CVD, and are in concordance with the findings of an earlier study in FH patients, in which homozygotes for the Ser311Cys variant of paraoxonase-2 seem to be protected against CVD. 32 Considering the limitations of association studies, we suggest our results should be replicated in addition to being performed in prospective studies of large and well-defined FH populations, in which genetic and environmental modifiers should be carefully monitored. The results of this hypothesis-generating study constitute a basis for further research and form a step forward in the unraveling of the underlying mechanisms of CVD in FH.
